-
5-strain Probiotic Formulation In Hormone Receptor-positive Breast Cancer Receiving Aromatase Inhibitor To Prevent Bone Loss
Jacksonville, FL
The purpose of this is a prospective, pilot, single-arm study to evaluate the median percent change in C-terminal telopeptide of type 1 collagen (CTx) after WBF-038 in early-stage breast cancer patients receiving aromatase inhibitors after 3- and 12-month treatment.
-
Impact Of Aromatase Inhibitor Therapy On Glucose Homeostasis And Diabetes Risk
Rochester, MN
This study assesses the effect of hormone directed treatment for breast cancer or ductal carcinoma in situ (DCIS) on glucose metabolism.
-
CBT Based Pain Management Program For The Treatment Of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) In Breast Cancer Survivors
Jacksonville, FL
We propose a novel intensive multidisciplinary intervention based on Cognitive Behavioral Therapy (CBT) Principles to treat AIMSS. CBT based approaches are effective in managing pain, but this approach has never been used to treat AIMSS. Our plan is to complete one treatment group a month with a census of 10 patients per group totaling 50 patients treated in approximately 5 months. We will run additional groups if needed to hit our target of 50 treated patients. Fifty additional patients will be randomized to the Control arm of the study (Treatment as usual). All patients will be assessed at ...
-
Testosterone in Treating Postmenopausal Patients with Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Mankato, MN
RATIONALE: Testosterone may help relieve moderate or severe arthralgia associated with the use of aromatase inhibitors, such as anastrozole or letrozole.
PURPOSE: This randomized phase III trial studies testosterone to see how well it works compared to placebo in treating postmenopausal patients with arthralgia caused by anastrozole or letrozole.
-
Letrozole In Treating Postmenopausal Women Who Have Received Hormone Therapy For Hormone Receptor-Positive Breast Cancer
Eau Claire, WI
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer.
PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer.
-
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
Mankato, MN
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer.
PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer.
-
Phase III Study To Assess AZD9833+ CDK4/6 Inhibitor In HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.